-
Xinhua Medical's 2 products obtained the second-class medical device registration certificate
Time of Update: 2022-01-12
The serum amyloid A detection kit (dry immunofluorescence method) has fast detection (15min), simple operation, convenient carrying, suitable for whole blood detection, small sample detection dosage, suitable for laboratory, pediatrics, emergency departments, etc.
-
Treating seasonal influenza genetically modified cattle to help produce broad-spectrum antibody therapies
Time of Update: 2022-01-12
SAB Biotherapeutics' technology platform uses genetically engineered cattle to produce a large number of fully humanized antibodies.
Reference materials:[1] SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus.
-
Anti-fungal drugs can actually fight cancer MIT team is pushing new anti-cancer drugs
Time of Update: 2022-01-12
▲The elevated level of hydrogen peroxide can be seen under a fluorescence microscope (picture source: reference [1], Credit: Massachusetts Institute of Technology)In their new study published in "Cell Chemistry and Biology", the authors screened a compound library containing 600 small molecules, which have been approved by the U.
-
Young women need to understand that there are still a few steps from cervical lesions to cervical cancer
Time of Update: 2022-01-12
From a statistical point of view, it usually takes 8 to 10 years from infection with HPV to cancer, but in recent years, the canceration time of patients treated by Liu Yanchun is much lower than this number, and the specific time varies from person to person .
-
Vaccine with "cupping"!
Time of Update: 2022-01-12
▲After direct injection and a combined suction process, changes in the concentration of neocoronavirus antibodies in mice (picture source: reference [1])Professor Lin Hao pointed out that this method provides a simple, cheap, and easy-to-scale platform for laboratory and clinical research and development of nucleic acid-based therapies and vaccines .
-
More than half of patients with psoriasis have almost completely eliminated skin symptoms. The first TYK2 inhibitor is about to come out?
Time of Update: 2022-01-12
Reference materials:[1] Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by US Food and Drug Administration and Validated by European Medicines Agency.
com/news /corporate-financial/2021/Bristol-Myers-Squibbs-Applications-for-Deucravacitinib-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Accepted-by-US-Food-and-Drug-Administration -and-Validated-by-European-Medicines-Agency/default.
-
EU approves 3 new indications for GlaxoSmithKline Mepolizumab
Time of Update: 2022-01-12
GlaxoSmithKline (GSK) recently announced that the European Commission (EC) has approved the anti-inflammatory drug Nucala (mepolizumab, mepolizumab), which is a specific targeted inhibitor of interleukin 5 (IL-5) Monoclonal antibody for the treatment of 3 types of eosinophil-driven diseases: hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granuloma Vasculitis (EGPA) .
-
Does taking statins really need to quit grapefruit?
Time of Update: 2022-01-12
Therefore, it is recommended that patients taking atorvastatin calcium, lovastatin, and simvastatin avoid taking large amounts of grapefruit .
-
Tumor-infiltrating lymphocytes and anti-PD-1 antibodies increase the remission rate of a variety of solid tumors
Time of Update: 2022-01-12
A few days ago, Iovance Biotherapeutics announced that the tumor infiltrating lymphocyte (TIL) therapy lifileucel, combined with the PD-1 inhibitor pembrolizumab (English trade name Keytruda), has been used in the treatment of multiple types of PD-1/PD that have not received PD-1/PD.
-
Ready-to-use T cell therapy enters the regulatory review stage for the first time, significantly improving patient survival
Time of Update: 2022-01-12
On November 30, 2021, Atara Biotherapeutics announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for the T cell immunotherapy tabelecleucel (tab-cel) for the treatment of EB virus (EBV) related Post-transplant lymphoproliferative disease (EBV+PTLD) .
-
New cutting-edge to improve the safety and durability of CAR-T therapy receives 250 million U.S. dollars from Blackstone
Time of Update: 2022-01-12
According to the terms of the agreement, Blackstone will provide up to US$250 million to support Autolus in advancing the clinical research and commercialization of obecabtagene autoleucel (obe-cel), an in-development CAR-T cell therapy targeting CD19, and development for the treatment of B cell malignancies The next generation of tumor products .
-
World Health Organization: What's the matter with the latest variant of the new crown virus?
Time of Update: 2022-01-12
▲The mutation carried by Omicron on the spike protein of the new coronavirus (picture source: gisaid.
Retrieved November 26, 2021, from https:// -new-south-african-variant-strain-lockdown-restrictions/[6] World Health Organization Tweet.
-
Innovative combination of RNA activation therapy for first-line treatment of advanced liver cancer enters the clinic
Time of Update: 2022-01-12
On December 1, 2021, the Cancer Institute of the National University of Singapore (NCIS) and MiNA Therapeutics jointly announced that MiNA's small-activated RNA therapy MTL-CEBPA, combined with standard treatments atezolizumab and bevacizumab (bevacizumab), is the first-line treatment for advanced liver The phase 1 clinical trial for patients with cell carcinoma (HCC) has completed the first patient's administration .
-
Rodents or asymptomatic carriers of SARS-like coronavirus
Time of Update: 2022-01-12
Science and Technology Daily, Beijing, November 23 (intern reporter Zhang Jiaxin) According to a study published in the latest issue of "Public Science Library Computational Biology", some ancestral rodents may be repeatedly infected with SARS-like coronaviruses, causing them to be against pathogens.
-
The strength target KRAS G12D: the unpreparable medicine is encircled and suppressed again
Time of Update: 2022-01-12
Relying on the characteristics of the newly introduced cysteine of KRAS G12C mutation that it is easy to form covalent bonds, a covalent small molecule inhibitor that can irreversibly target and bind to the cysteine residues on codon 12 of KRAS was designed, and finally the drug was marketed.
-
Gene therapy phase 3 clinical results achieved key results, 67% of patients' skin wounds healed completely
Time of Update: 2022-01-12
On November 29, 2021, Krystal Biotech announced that a pivotal phase 3 clinical trial of Vyjuvek (beremagene geperpavec, B-VEC), a topical topical gene therapy under investigation, has achieved positive top-line results .
-
A number of domestic new crown drugs entering clinical trials are expected to become "new weapons" in the fight against the epidemic
Time of Update: 2022-01-12
Xinhua News Agency, Beijing, November 19 (Reporters Dong Ruifeng, Xu Penghang) The reporter learned from the State Council’s Joint Prevention and Control Mechanism Scientific Research Team that China’s self-developed new crown drugs have completed phase III clinical trials and are applying for conditional listing .
-
Reduce the risk of early breast cancer recurrence by 42%
Time of Update: 2022-01-12
S. FDA has granted the PARP inhibitor olaparib (English trade name: Lynparza) the priority review qualification for the Supplementary New Drug Application (sNDA) for adjuvant therapy High-risk HER2-negative early breast cancer patients with BRCA mutations have received chemotherapy neoadjuvant or adjuvant therapy .
-
New research shows that some cancer drugs have the potential to treat Alzheimer's disease
Time of Update: 2022-01-12
Combining the analysis of brain protein changes in this population and the research of laboratory experiments in animal models and cell cultures may help scientists to identify existing drugs more quickly to test them for Alzheimer's disease The potential of interventions .
-
Scientific innovation supervision "can have both fish and bear's paws"
Time of Update: 2022-01-12
The first batch of cooperative drug regulatory agencies planned by Orbis include the US FDA, Australian TGA, and Health Canada .
In December 2016, the United States promulgated the "21st Century Recovery Act", requiring the FDA to include Real-World Evidence (RWE) in the review process of drugs and medical devices.
